Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has launched generic Xeloda in the US for the treatment of breast, colon and colorectal and other cancers. In September 2013, the US Food and Drug Administration (FDA) approved Teva's generic versions of Xeloda 150 and 500 milligram tablets, September 16, 2013 and the treatmewnt was launched in Friday in accordance with a settlement agreement.
Brand Xeloda, made by Genentech Inc., had $754 million in US sales in 2013, according to IMS sales data.
Published by Globes [online], Israel business news - www.globes-online.com - on March 9, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014